Mark‐David Levin
YOU?
Author Swipe
View article: Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma
Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma Open
Standard pomalidomide dosing (4 mg/day for 21 of 28 days) achieved the most robust pharmacokinetic (PK) and pharmacodynamic (PD) effects. Daily dosing with pomalidomide 2 mg is a safe alternative for patients at risk of toxicity; alternate…
View article: Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first‐line therapy irrespective of frailty levels
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first‐line therapy irrespective of frailty levels Open
The treatment landscape for older patients with multiple myeloma (MM) has rapidly evolved with the introduction of CD38‐targeting antibodies. Yet, outcomes remain highly variable and are only partially explained by frailty status. To addre…
View article: The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL Open
Venetoclax-obinutuzumab (Ven-Obi) is a standard first-line therapy for chronic lymphocytic leukemia (CLL). The impact of age, fitness, and dose reductions remains unclear. We analyzed patients treated with Ven-Obi in the CLL13 and CLL14 tr…
View article: Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial
Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial Open
Frailty, rather than age alone, is a key determinant of outcomes in older patients with multiple myeloma (MM), yet frailty assessments are often lacking in clinical trials. Consequently, data on the efficacy and tolerability of novel treat…
View article: OT02 | CLL18/MOIRAI TRIAL AIMING TO ESTABLISH MEASUREMENT OF INDIVIDUAL RESIDUAL DISEASE FOR ADJUSTMENT OF TREATMENT DURATION TO IMPROVE OUTCOMES IN TREATMENT‐NAIVE CLL/SLL
OT02 | CLL18/MOIRAI TRIAL AIMING TO ESTABLISH MEASUREMENT OF INDIVIDUAL RESIDUAL DISEASE FOR ADJUSTMENT OF TREATMENT DURATION TO IMPROVE OUTCOMES IN TREATMENT‐NAIVE CLL/SLL Open
View article: Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial Open
Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) are treated with fixed-duration B-cell lymphoma 2 inhibitors + CD20 monoclonal antibodies or continuous Bruton tyrosine kinase (BTK) inhibitors. Although continuous…
View article: Treatment‐Free Remission Outcomes in a <i><scp>BCR</scp>::<scp>ABL1</scp></i> Digital <scp>PCR</scp> Selected Clinical Cohort of <scp>CML</scp> Patients
Treatment‐Free Remission Outcomes in a <i><span>BCR</span>::<span>ABL1</span></i> Digital <span>PCR</span> Selected Clinical Cohort of <span>CML</span> Patients Open
Approximately 40%–60% of patients reaching a stable deep molecular response during TKI treatment will maintain a state of remission after TKI discontinuation, denoted as treatment‐free remission (TFR). Depth of molecular response assessed …
View article: Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases
Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases Open
View article: Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients Open
View article: Causes of death among patients diagnosed with chronic lymphocytic leukemia: A population‐based study in the Netherlands, 1996–2020
Causes of death among patients diagnosed with chronic lymphocytic leukemia: A population‐based study in the Netherlands, 1996–2020 Open
Chronic lymphocytic leukemia (CLL) manifests heterogeneously with varying outcomes. This population‐based study examined causes of death (CODs), as registered by the physician who established the death, among 20,588 CLL patients diagnosed …
View article: Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes Open
In 2015, the International Myeloma Working Group (IMWG) introduced a frailty index (IMWG-FI), as a means to quantify fragility of patients with multiple myeloma (MM). This index categorizes patients into three groups: fit, intermediate-fit…
View article: Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial Open
View article: First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial Open
View article: Supplementary Figure S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S5. Stimulated cytokine response in patients with or without pre-treatment infections.
View article: Supplementary Table S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S5. Baseline patient- and disease related characteristics for patients with or without history of infections.
View article: Supplementary Figure S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S4. Changes in immune cell activation marker expression during targeted treatment.
View article: Supplementary Table S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S3. Supplementary Table S3. Representativeness of study participants.
View article: Supplementary Figure S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S5. Stimulated cytokine response in patients with or without pre-treatment infections.
View article: Data from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Data from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Purpose:Patients with chronic lymphocytic leukemia (CLL) have increased risk of severe infections. Although adaptive immune dysfunction is well described, clinical tools for identifying patients at risk are lacking, warranting investigatio…
View article: Supplementary Table S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S1. Overview over the applied 10-color flow cytometry panel for the two tubes included in this study.
View article: Supplementary Table S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S5. Baseline patient- and disease related characteristics for patients with or without history of infections.
View article: Supplementary Figure S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S1. Innate immune responses at baseline vs 2-3 cycles of BTKi.
View article: Supplementary Table S2 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S2 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S2. Gating strategies for the immune cell subset populations included in this study.
View article: Supplementary Figure S6 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S6 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S6. Clinical trajectories with 3 years of follow up.
View article: Supplementary Table S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S4. Baseline patient- and disease related characteristics.
View article: Supplementary Table S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S3. Supplementary Table S3. Representativeness of study participants.
View article: Supplementary Figure S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S3. Changes in innate immune cell subsets during targeted treatment and correlations with stimulated cytokine responses.
View article: Supplementary Table S2 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S2 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S2. Gating strategies for the immune cell subset populations included in this study.
View article: Supplementary Table S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Table S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Table S1. Overview over the applied 10-color flow cytometry panel for the two tubes included in this study.
View article: Supplementary Figure S6 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Supplementary Figure S6 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials Open
Supplementary Figure S6. Clinical trajectories with 3 years of follow up.